NPPB and cardiomyopathy: In summary, chronic treatment with DOX at 3 mg/kg/week for 2 weeks led to increases in miR-208b, miR-216b and miR-367, with fold change intensities comparable to those shown by genomic cardiomyopathy indicators (Ankrd/Carp, Nppb, Myh7 and Myh6) (Figure 2 and Table 1), suggesting that microRNAs may enhance the predictivity of established genomic indicators of drug-induced cardiomyopathy (e.g. myosin genes, troponins, natriuretic peptides) when assessing the potential for drug-induced cardiotoxicity.